Back

PCSK9 Inhibitors: deep dive into guidelines and clinical data

9 November 2019 (12:40 - 13:05)
Organised by:
Congress Presentation Part of: Understanding PCSK9 Inhibitors: what, when and why? PCSK9-Antagonists ESC Premium Access ESC Asia with APSC & AFC

About the speaker

Photo
Associate Professor Karam Kostner

University of Queensland, Brisbane (Australia)

3 More presentations in this session

Presentation thumbnail
Welcome and opening remarks: confronting the burden of LDL-C in Asia
Associate Professor J. Tan (Singapore, SG)
Slides Video
Presentation thumbnail
Treating patients in the real world
Professor S. Uemura (Kurashiki, JP)
Video
Presentation thumbnail
Questions and answers and closing remarks
Associate Professor J. Tan (Singapore, SG)
Video

Access the full session

Session thumbnail
Understanding PCSK9 Inhibitors: what, when and why?

The Event

Event poster

ESC Asia with APSC & AFC

9 November 2019 12:40 CET
You may be interested in
thumbnail
Congress Presentation
What have we learned? Long-term safety and efficacy of inclisiran
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
thumbnail
Congress Presentation
PCSK9 inhibition: new insights

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources